Organizations: 1Georgia State University, Atlanta, GA, USA · 2Georgia Institute of Technology, Atlanta, GA, USA
Abstract
Antibody design methods condition on antigen structure to generate complementarity-determining regions (CDR), yet a systematic evaluation of baseline methods reveals that they largely ignore the antigen input. We identify three failure modes that explain this behavior. Antigen blindness arises because models derive predictions from antibody framework context rather than antigen information, producing nearly identical CDRs regardless of the target. Vocabulary collapse reduces predicted amino acids to three to five per position, far below the ground truth distribution in native sequences. Moreover, any model trained with standard per-position cross-entropy converges to the positional marginal distribution, making it provably unable to produce antigen-specific sequence predictions. We propose a novel encoder-decoder architecture called AgForce, that uses a graph neural network (GNN) as the encoder and specialized decoders for sequence-structure co-design. Specifically, we apply framework dropout, gated bottlenecks, and hyperbolic cross attention that prevent the antibody shortcut path. In the decoder, a Mixture Density Network (MDN) sequence head with Potts-like pairwise coupling and annealed Multiple Choice Learning (aMCL) replaces the cross-entropy objective with a multi-component distribution whose optimal solution differs from the positional marginal. An antigen cycle consistency head routes gradients through the sequence decoder, forcing predicted distributions to encode antigen identity. AgForce achieves the best binding quality and sequence recovery simultaneously on the CHIMERA-Bench dataset, improving amino acid recovery by 8% over the strongest sequence baseline while surpassing the baselines across all interface metrics, and nearly doubling the effective vocabulary of GNN methods. The source code is available at: https://github.com/mansoor181/ag-force.git
Antibodies are essential proteins that play a central role in immune recognition by binding specific antigen molecules. Although recent protein language models have enabled progress in single-chain protein modeling and generation, they often fall short in antigen-specific antibody design, where effective modeling requires explicit pairing between antibody and antigen, particularly at the epitope level. To address these limitations, we introduce AAMFM, an Antigen-specific Antibody Multimodal Foundation Model that learns unified representations of antibody sequences and structures conditioned on antigen context. AAMFM incorporates rich antigen information including geometric interfaces and epitope annotations via a cross-modal adapter, enabling joint modeling of antibody-antigen interactions in a shared latent space. To further guide the model toward functional relevance, we fine-tune AAMFM using Calibrated Direct Preference Optimization (Cal-DPO), leveraging preference signals extracted from a strong structural prior to align learning with binding-specific objectives. Extensive experiments demonstrate that AAMFM achieves state-of-the-art performance in functional antibody design, revealing its potential for antigen-specific antibody engineering. Our code is available at https://github.com/XL-S224/AAMFM.
Computational antibody CDR design methods condition on antigen structure to generate binding loops. Yet, the existing architectures conflate two fundamentally distinct sub-problems: identifying which CDR positions will contact the antigen, and selecting amino acids at those positions. This forces models to learn contact reasoning implicitly through uniform message passing, diluting antigen signal across all positions equally. We introduce ConTact, a contact-then-act architecture that explicitly decomposes CDR design into three cascaded stages: learning surface complementarity fingerprints, predicting CDR-antigen contacts, and injecting contact-gated antigen features into the prediction head. A distance-biased cross-attention module encodes geometric priors favoring spatial neighbors, while a contact-weighted cross-entropy loss concentrates gradient signal on binding-critical positions. On the CHIMERA-Bench dataset, ConTact achieves the lowest backbone RMSD on every split (a 5 to 6% improvement over the best baseline) and the best fraction of native contacts, interface RMSD, and epitope F1 on the antigen-fold and temporal splits, while remaining competitive on the harder epitope-group split. The source code is available at: https://github.com/mansoor181/ConTact.git
Equivariant graph neural network (GNN) methods for antibody complementarity-determining region (CDR) design achieve the highest sequence recovery but suffer from severe vocabulary collapse. The current best GNN methods over-predict very few amino acids, such as tyrosine and glycine, while ignoring functionally important residues. We trace this failure to GNN encoders learning amino acid distributions de novo from limited structural data, discarding substitution patterns encoded in evolutionary databases. To resolve this, we propose EvoStruct, which bridges a frozen protein language model (PLM) with 3D structural context from an E(3)-equivariant GNN via a cross-attention adapter. Unlike prior PLM-structure adapters for general protein design, EvoStruct targets the vocabulary collapse problem specific to CDR design through progressive PLM unfreezing and R-Drop consistency regularization. On the CHIMERA-Bench dataset, EvoStruct achieves the highest amino acid recovery and lowest perplexity among several antibody design methods, improving sequence recovery by 16% and reducing perplexity by 43% relative to the best GNN baselines, while recovering 2.3x greater amino acid diversity and the highest binding-pair correlation with ground truth.